Potential treatment for glioblastoma multiforme
TVI-Brain-1 immunotherapy, a potential treatment for glioblastoma multiforme, developed by TVAX Biomedical, has received Fast track designation by the U.S. Food and Drug Administration. Fast track is given to an experimental treatment for a disease that does not yet have one, or to a treatment that offers better results than existing treatments, in order to facilitate its development.
